Advertisement
Document › Details
Mablink Bioscience SAS. (10/18/23). "Press Release: Mablink Bioscience Enters an Agreement to be Acquired by Lilly". Lyon.
Organisation | Mablink Bioscience SAS | |
Organisation 2 | Eli Lilly & Co. Inc. (NYSE: LLY) | |
Product | PSARlink™ drug-linkers | |
Product 2 | antibody-drug conjugate (ADC) | |
Index term | Mablink Bioscience–Lilly: investment, 202310 acquisition of Mablink Bioscience by Eli Lilly | |
Person | Lafay, Jean-Guillaume (Mablink Bioscience 202104 CEO + Co-Founder) | |
The pending acquisition reflects the potential of Mablink’s existing pipeline and proprietary PSARLink™ technology for development of additional drug conjugates.
Mablink Bioscience (“Mablink”), a pre-clinical biotechnology company pioneering the development of next-generation antibody-drug conjugates (ADCs) via its PSARLink™ proprietary platform, today announced an agreement to be acquired by Eli Lilly and Company (“Lilly”).
PSARlink™, an innovative hydrophilic linker using a polysarcosine arm, holds potential for broadening the therapeutic index of ADCs to unleash their full therapeutic impact.
Jean-Guillaume Lafay, Mablink’s Chief Executive Officer, stated: “Mablink’s agreement to be acquired by Lilly is a strong endorsement of our approach, our technology and our team. The values we share with Lilly, and our combined expertise are also a unique opportunity to leverage Mablink’s capabilities and endeavors to potentially bring transformative therapies to cancer patients with high unmet medical needs. Our thanks go to all inside and outside Mablink who have supported our efforts and development since inception.”
The transaction is subject to approval from the French Ministry of the Economy.
About PSARlink™
PSARlink™ linkers chemically and physically link an antibody and a chosen cytotoxic molecule to selectively deliver the payload to tumor cells. PSARlink™'s unique structure "masks" the cytotoxic molecules, especially hydrophobic compounds, enabling them to stay longer in the body to facilitate tumor cell killing. PSARlink™-based ADCs have also demonstrated an improved therapeutic index in animal models.
About Mablink Bioscience
Mablink Bioscience is a biotechnology company developing the next generation of an emerging class of cancer drugs called antibody-drug conjugates (ADCs). Mablink’s patented hydrophilic drug-linker technology, PSARLink™, enables the design of homogeneous, plasma- stable, next generation ADCs with high DAR (drug-to-antibody ratio) while maintaining excellent pharmacological properties and tolerability. Mablink was funded by a seed round led by Elaia Partners in 2021, along with UI Investissement (advised by Mérieux Equity Partners) and Relyens Innovation Santé (advised by Turenne Capital), and a series A financing led by Sofinnova Partners and Mérieux Equity Partners in July 2022.
For more information, please visit https://mablink.com
Press Contacts:
Lilly:
Lauren Cohen
617.678.2067
lcohen@loxooncology.com
Record changed: 2024-03-30 |
Advertisement
More documents for Eli Lilly (Group)
- [1] Mablink Bioscience SAS. (10/14/22). "Press Release: Mablink Bioscience Announces a €31 Million Series A Funding Round Led by Sofinnova Partners and Mérieux Equity Partners". Lyon....
- [2] Emergence Therapeutics AG. (12/7/21). "Press Release: Emergence Therapeutics Raises €87 Million Series A Financing to Advance Nectin-4 ADC". Duisburg....
- [3] Mablink Bioscience SAS. (10/21/21). "Press Release: Mablink Bioscience and Emergence Therapeutics Enter into a Licensing Agreement to Develop Antibody Drug Conjugate as a Potential Cancer Therapy". Lyon & Duisburg....
- [4] Mablink Bioscience SAS. (4/27/21). "Press Release: Mablink Bioscience, the Next Generation ADC Company, Raises €4 Million from a Syndicate of Private Investors". Lyon....
- [5] DiCE Molecules SV, Inc.. (1/8/21). "Press Release: DiCE Molecules Announces $80 Million Series C Financing. Jake Simson, Ph.D., Joins Board of Directors". South San Francisco, CA....
- [6] High-Tech Gründerfonds Management GmbH. (11/25/20). "Press Release: Emergence Therapeutics Announces a Bumped-up Follow-on Seed Round Financing"....
- [7] Adocia S.A.. (10/11/18). "Press Release: Adocia Informs about a Civil Action Filed by Eli Lilly". Lyon....
- [8] Adocia S.A.. (8/30/18). "Press Release: Adocia Announces Update to Second Arbitration Against Eli Lilly & Company". Lyon....
- [9] Adocia S.A.. (8/20/18). "Press Release: American Arbitration Association Panel Finds In Favor Of Adocia In First Phase Of Arbitration Against Eli Lilly". Lyon....
- [10] Sigilon Therapeutics, Inc.. (8/14/18). "Press Release: Sigilon Therapeutics Announces Leadership Transition and Appoints Rare Disease Pioneer Rogerio Vivaldi, M.D., as Chief Executive Officer". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top